HF
CLDI icon

HRT Financial’s Calidi Biotherapeutics CLDI Stock Holding History

HRT Financial’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-633
Closed -$2K – 4340
2026
Q1 		$2K Buy
+633
New +$7.61K ﹤0.01% 3673
2025
Q3 		– Sell
-227
Closed -$10K – 2937
2025
Q2 		$10K Buy
+227
New +$17.6K ﹤0.01% 2453
2025
Q1 		– Sell
-82
Closed -$18K – 2609
2024
Q4 		$18K Buy
+82
New +$24.6K ﹤0.01% 2218
2024
Q3 		– Sell
-53
Closed -$20K – 2511
2024
Q2 		$20K Buy
53
+46
+657% +$23.5K ﹤0.01% 1934
2024
Q1 		$7K Sell
7
-2
-22% -$3.27K ﹤0.01% 2090
2023
Q4 		$25K Buy
9
+4
+80% +$17.2K ﹤0.01% 2018
2023
Q3 		$34K Sell
5
-1
-17% -$16.2K ﹤0.01% 2028
2023
Q2 		$113K Hold
6
– – ﹤0.01% 1949
2023
Q1 		$111K Hold
6
– – ﹤0.01% 2042
2022
Q4 		$110K Hold
6
– – ﹤0.01% 2048
2022
Q3 		$107K Buy
+6
New +$115K ﹤0.01% 2380

Other funds holding CLDI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HRT Financial's CLDI Position: Q2 2026 in Review

HRT Financial sold out of Calidi Biotherapeutics (CLDI) in Q2 2026, closing a stake of 633 shares — an estimated $2K sold.

HRT Financial first reported a position in CLDI in Q3 2022 and held it in 11 quarters. The position peaked at $113K in Q2 2023. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

  • HRT Financial reported no remaining Calidi Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 633 Calidi Biotherapeutics shares in Q2 2026, an estimated $2K.
  • HRT Financial first reported a position in Calidi Biotherapeutics in Q3 2022 and held it in 11 quarters.
  • HRT Financial's Calidi Biotherapeutics position peaked at $113K in Q2 2023.
  • 22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.